The FDA approved Novartis' revolutionary CAR-T cell leukemia therapy, which uses patients' genetically modified immune cells to fight the disease — at the cost of $475,000 per treatment, according to STAT. The drug, Kymriah, is the first CAR-T therapy to come before the FDA and was approved for the treatment of patients up to 25 years old with relapsed acute lymphoblastic leukemia. A clinical trial of the leukemia drug deemed a "breakthrough" by physicians revealed 83 percent of patients treated with CAR-T cell therapy have gone into remission. While the price tag of $475,000 per treatment seems staggering, it is...
